A Phase IV, Open-Label Administration (The Trial Statistician and Laboratory Technicians will be Blinded to Group Assignment), Randomized (Group 1 and 2), Parallel-Group, Multicenter Trial to Evaluate the Immunogenicity and Safety of 2 Doses of

Project Details

StatusFinished
Effective start/end date3/08/1231/08/15

Funding

  • Sanofi Pasteur, Inc.: $36,128.00

Keywords

  • Biotechnology & Drug Development, Infectious Diseases